Infliximab Concentrations in Participants with Moderate to Severe COVID‐19

Infliximab Concentrations in Participants with Moderate to Severe COVID‐19

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical pharmacology 2024-04, Vol.64 (4), p.490-491
Hauptverfasser: Balevic, Stephen J., Dandachi, Dima, Dixon, Danielle, Hoetelmans, Richard M.W., Bozzette, Sam, McCarthy, Matthew W.
Format: Artikel
Sprache:eng
Schlagworte:
COVID-19
Infliximab
Monoclonal antibodies
pharmacokinetics
Tumor necrosis factor-α
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 491
container_issue 4
container_start_page 490
container_title Journal of clinical pharmacology
container_volume 64
creator Balevic, Stephen J.
Dandachi, Dima
Dixon, Danielle
Hoetelmans, Richard M.W.
Bozzette, Sam
McCarthy, Matthew W.
description
doi_str_mv 10.1002/jcph.2388
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2895711197</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2987009196</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3888-e14a5d5029b83be418e57664711a95842b57860844144e9d5dc18760469f4e803</originalsourceid><addsrcrecordid>eNp1kLtOwzAUhi0EglIYeAEUiQWGtLZjJ_aIwqVFRa3EZbVyOVVdpUmxE0o3HoFn5ElwaGFAYjrLp0__-RA6IbhHMKb9ebac9WggxA7qEM6pz0LMdlEHY0l8GmF8gA6tnWNMQsbJPjoIBA6IoGEHjYbltNBvepGkXlyVGZS1SWpdldbTpTdJTK0zvUzK2norXc-8-yoHB4BXV94DvIIBLx4_D68-3z-IPEJ706SwcLy9XfR0c_0YD_zR-HYYX478zG0UPhCW8JxjKlMRpMCIAB6FIYsISSQXjKY8EiEWjBHGQOY8z4iI3EuhnDJw07vofONdmuqlAVurhbYZFEVSQtVYRYXkTkZk5NCzP-i8akzp1ikqRdQWkqGjLjZUZiprDUzV0rgkZq0IVm1i1SZWbWLHnm6NTbqA_Jf8aeqA_gZY6QLW_5vUXTwZfCu_ACujg1w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2987009196</pqid></control><display><type>article</type><title>Infliximab Concentrations in Participants with Moderate to Severe COVID‐19</title><source>Wiley Online Library - AutoHoldings Journals</source><creator>Balevic, Stephen J. ; Dandachi, Dima ; Dixon, Danielle ; Hoetelmans, Richard M.W. ; Bozzette, Sam ; McCarthy, Matthew W.</creator><creatorcontrib>Balevic, Stephen J. ; Dandachi, Dima ; Dixon, Danielle ; Hoetelmans, Richard M.W. ; Bozzette, Sam ; McCarthy, Matthew W. ; ACTIV‐1 Study Team ; the ACTIV‐1 Study Team</creatorcontrib><identifier>ISSN: 0091-2700</identifier><identifier>EISSN: 1552-4604</identifier><identifier>DOI: 10.1002/jcph.2388</identifier><identifier>PMID: 38031826</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>COVID-19 ; Infliximab ; Monoclonal antibodies ; pharmacokinetics ; Tumor necrosis factor-α</subject><ispartof>Journal of clinical pharmacology, 2024-04, Vol.64 (4), p.490-491</ispartof><rights>2023, The American College of Clinical Pharmacology.</rights><rights>2024, The American College of Clinical Pharmacology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3888-e14a5d5029b83be418e57664711a95842b57860844144e9d5dc18760469f4e803</citedby><cites>FETCH-LOGICAL-c3888-e14a5d5029b83be418e57664711a95842b57860844144e9d5dc18760469f4e803</cites><orcidid>0000-0002-4016-1680</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjcph.2388$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjcph.2388$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27931,27932,45581,45582</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38031826$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Balevic, Stephen J.</creatorcontrib><creatorcontrib>Dandachi, Dima</creatorcontrib><creatorcontrib>Dixon, Danielle</creatorcontrib><creatorcontrib>Hoetelmans, Richard M.W.</creatorcontrib><creatorcontrib>Bozzette, Sam</creatorcontrib><creatorcontrib>McCarthy, Matthew W.</creatorcontrib><creatorcontrib>ACTIV‐1 Study Team</creatorcontrib><creatorcontrib>the ACTIV‐1 Study Team</creatorcontrib><title>Infliximab Concentrations in Participants with Moderate to Severe COVID‐19</title><title>Journal of clinical pharmacology</title><addtitle>J Clin Pharmacol</addtitle><subject>COVID-19</subject><subject>Infliximab</subject><subject>Monoclonal antibodies</subject><subject>pharmacokinetics</subject><subject>Tumor necrosis factor-α</subject><issn>0091-2700</issn><issn>1552-4604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp1kLtOwzAUhi0EglIYeAEUiQWGtLZjJ_aIwqVFRa3EZbVyOVVdpUmxE0o3HoFn5ElwaGFAYjrLp0__-RA6IbhHMKb9ebac9WggxA7qEM6pz0LMdlEHY0l8GmF8gA6tnWNMQsbJPjoIBA6IoGEHjYbltNBvepGkXlyVGZS1SWpdldbTpTdJTK0zvUzK2norXc-8-yoHB4BXV94DvIIBLx4_D68-3z-IPEJ706SwcLy9XfR0c_0YD_zR-HYYX478zG0UPhCW8JxjKlMRpMCIAB6FIYsISSQXjKY8EiEWjBHGQOY8z4iI3EuhnDJw07vofONdmuqlAVurhbYZFEVSQtVYRYXkTkZk5NCzP-i8akzp1ikqRdQWkqGjLjZUZiprDUzV0rgkZq0IVm1i1SZWbWLHnm6NTbqA_Jf8aeqA_gZY6QLW_5vUXTwZfCu_ACujg1w</recordid><startdate>202404</startdate><enddate>202404</enddate><creator>Balevic, Stephen J.</creator><creator>Dandachi, Dima</creator><creator>Dixon, Danielle</creator><creator>Hoetelmans, Richard M.W.</creator><creator>Bozzette, Sam</creator><creator>McCarthy, Matthew W.</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4016-1680</orcidid></search><sort><creationdate>202404</creationdate><title>Infliximab Concentrations in Participants with Moderate to Severe COVID‐19</title><author>Balevic, Stephen J. ; Dandachi, Dima ; Dixon, Danielle ; Hoetelmans, Richard M.W. ; Bozzette, Sam ; McCarthy, Matthew W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3888-e14a5d5029b83be418e57664711a95842b57860844144e9d5dc18760469f4e803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>COVID-19</topic><topic>Infliximab</topic><topic>Monoclonal antibodies</topic><topic>pharmacokinetics</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Balevic, Stephen J.</creatorcontrib><creatorcontrib>Dandachi, Dima</creatorcontrib><creatorcontrib>Dixon, Danielle</creatorcontrib><creatorcontrib>Hoetelmans, Richard M.W.</creatorcontrib><creatorcontrib>Bozzette, Sam</creatorcontrib><creatorcontrib>McCarthy, Matthew W.</creatorcontrib><creatorcontrib>ACTIV‐1 Study Team</creatorcontrib><creatorcontrib>the ACTIV‐1 Study Team</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Balevic, Stephen J.</au><au>Dandachi, Dima</au><au>Dixon, Danielle</au><au>Hoetelmans, Richard M.W.</au><au>Bozzette, Sam</au><au>McCarthy, Matthew W.</au><aucorp>ACTIV‐1 Study Team</aucorp><aucorp>the ACTIV‐1 Study Team</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Infliximab Concentrations in Participants with Moderate to Severe COVID‐19</atitle><jtitle>Journal of clinical pharmacology</jtitle><addtitle>J Clin Pharmacol</addtitle><date>2024-04</date><risdate>2024</risdate><volume>64</volume><issue>4</issue><spage>490</spage><epage>491</epage><pages>490-491</pages><issn>0091-2700</issn><eissn>1552-4604</eissn><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38031826</pmid><doi>10.1002/jcph.2388</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-4016-1680</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0091-2700
ispartof Journal of clinical pharmacology, 2024-04, Vol.64 (4), p.490-491
issn 0091-2700
1552-4604
language eng
recordid cdi_proquest_miscellaneous_2895711197
source Wiley Online Library - AutoHoldings Journals
subjects COVID-19
Infliximab
Monoclonal antibodies
pharmacokinetics
Tumor necrosis factor-α
title Infliximab Concentrations in Participants with Moderate to Severe COVID‐19
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T03%3A52%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Infliximab%20Concentrations%20in%20Participants%20with%20Moderate%20to%20Severe%20COVID%E2%80%9019&rft.jtitle=Journal%20of%20clinical%20pharmacology&rft.au=Balevic,%20Stephen%20J.&rft.aucorp=ACTIV%E2%80%901%20Study%20Team&rft.date=2024-04&rft.volume=64&rft.issue=4&rft.spage=490&rft.epage=491&rft.pages=490-491&rft.issn=0091-2700&rft.eissn=1552-4604&rft_id=info:doi/10.1002/jcph.2388&rft_dat=%3Cproquest_cross%3E2987009196%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2987009196&rft_id=info:pmid/38031826&rfr_iscdi=true